The European Patent Office (EPO) has granted patent EP3467503B1, covering a method and kit for detecting lung cancer. The patent was officially granted on March 18, 2026, with Daisuke Nakata identified as the inventor. This patent falls under IPC classifications G01N 33/574 and C12N 9/16, indicating its relevance to diagnostic methods and specific enzymes.

This patent grant represents a new intellectual property right for the inventor and potentially their affiliated entities. While not imposing direct compliance obligations on other entities, it signifies a new patented technology in the field of lung cancer diagnostics. Companies operating in this space, particularly drug manufacturers and medical device makers, should be aware of this granted patent to ensure they do not infringe upon the intellectual property rights associated with this method and kit. No specific compliance actions are mandated by this notice, but legal and R&D departments may wish to review the patent details for strategic or competitive awareness.